Index

Access to medical procedures 48–52
  case against patent protection 50
  control, question of 50–52
  demand and supply, dynamics of 51–52
  increased costs of health care 52–53
  meanings 49
  methods of medical treatment 48–50

Actavis v Merck 361–372
  Court of Appeal 362–364
  ‘different medical condition’ 368
  distinct and different medical condition 366
  first instance 361–362
  novel technical features 363
  obviousness 364–365
  precedent 371
  which novelty? 370–371

Animals 101–112
  agricultural methods 102
  application by TBAs 103–104
  EBA 111–112
  ectoparasitic infestations of pigs 103–104
  immunostimulation 107–108
  incidental objectives 106–111
  increased meat production 108–109
  industrial application 101–106
  legislative history 104–105
  method of treatment by therapy 109–110
  reformulation of exclusion 106
  surgical methods 111–112
  therapy, meaning 110

Arguments against patent protection 41–70, 443–444
  access to medical procedures 48–52
  case against patent protection 50
  control, question of 50–52
  demand and supply, dynamics of 51–52
  increased costs of health care 52–53
  meanings 49
  methods of medical treatment 48–50
  breach of patient’s privacy 68–69
  disclosure 69
  right to privacy 68–69
  code of ethics 61–62
  compulsory licences 53–58
  Act of 1977 54–55
  case for 56
  costs, and 57
  intellectual property rights 53
  limitations 57–58
  meaning 53
  public health, and 55–56
  emotive arguments 41–42
  Hippocratic Oath 61–62
  methods of medical treatment 63–65
  specific to medical profession 63–64
  incentive structures 66–68
  alternative 67
  methods 43–45
  pharmaceutical products 43–45
  physician liberty and autonomy 58–60
  factors affecting judgment 59
  physician/patient relationship 60–61
  products 43–45
  public health implications 45–58
  rationale for exclusion 42
  right to health 46–48
Medical patent law – the challenges of medical treatment

sharing norm 62–63
erosion of 65
methods of medical treatment 63–65
nature of 64–65
TRIPS Agreement 47
Arguments for and against patent protection 443–447
Arguments for patent protection 9–40, 444–445
balancing exercise 443
direct control over supply of invention 444
economic purpose 10
economic rationale 444
ethical justifications 443–444
incentive to disclose 11–13
Chamberlain family 12
methods of medical treatment 11–13
research, and 13
incentive to invent/innovate 14–23
breadth of medical science 22
cost-benefit analysis, and 22
cost of research, and 17
Gocyk-Farber on 21–22
high development cost inventions 20–23
methods of medical treatment 15–18
promotion of R&D 16
reward theory 14–15
SET Patent 18–20
utilitarian principles 14
liberty/autonomy 34–39
collaborative research efforts 38
Hegel on 36
Locke’s theory of property 35–36
methods of medical treatment 38–39
property rights, justification for 36–37
Radin on 37
rights of creator of invention 39
prospect theory 23–26
Kitch on 23–24
limitation 24
methods of medical treatment 25–26
simple methods of treatment 26
treatment regimes 25–26
rationales 9–10
rent dissipation theory 27–31
Grady and Alexander on 27–30
methods of medical treatment 28–31
reward/desert 31–34
endocrine therapy 33
identity of creator 34
methods of medical treatment 33–34
philosophical difficulties 32
value of product to society 33–34
Australia
judicial determination of exclusion 434
public interest 446
Commonwealth
manner of new manufacture see Manner of new manufacture
Contraceptive methods 97–100
feminine hygiene device 99–100
LHRH composition 97
manner of new manufacture see also Manner of new manufacture
arrangement of pills on card 317–319
hormonal drugs 316
method of medical treatment, whether 316
pack claims 316, 317–320
process claims 316
royal prerogative 317
setting limits 320–321
method of treatment by therapy, whether 97–98
personal use 98–100
susceptible to industrial application, whether 98–100
Cosmetic methods 89–96
acceptable form of claim 95–96
anti-snoring means 94
appetite suppressant 94
cleaning plaque 93–94
industrial application 94–95
meaning 90
Index

not patentable 93–94
patentable 90–92
Patents Act 1977 see Patents Act 1977
thenoyl peroxide 90
therapeutic use, and 91–92

Diagnostic methods 184–228
application of principles 208–218
consistency of approach 218
defining diagnostic methods 208–212
interaction with human or animal body 213
intermediate steps 216–218
methodological issues: early view 213
methodological issues: more recent view 214–216
no diagnosis 209
no diagnosis and not practised on body 210
only examination and data gathering phase present 210–212
practised on human or animal body 213
‘applied to the human or animal body’ 188–189
blood extraction method 193–194
broad approach 196–201
application of general principles 200–201
blood extraction method 199
defining diagnostic methods 196–197
medical practitioners, involvement of 197–198
mental acts 196–197
practised on human or animal body 198–199
ultimate responsibility of physician 198
defining 189–192
EPO jurisprudence 439–440
examination phase 193
four-pronged test 190–191
legislative history 187–189
medical practitioners, involvement of 192–194
narrow approach 189–196
new medical technology 218–228
EU Biotech Directive see EU Biotech Directive
genetic diagnostic testing 219–221, 223–227
methods of medical treatment 219–221
morality, and 222–223
ordre public 222–223
patent law, and 218–219
non-invasive measurement 191–192
Patents Act 1977 see Patents Act 1977
practised on human or animal body 194–196
reconciling two approaches 201–208
delineating scope of definition 204–205
diagnosing diagnostic methods 201–206
essential features of claims 205–206
first principles 202
intellectual exercise 203–204
medical practitioners, involvement of 206–207
multi-step approach 202–203
practised on human or animal body 207–208
rationale for exclusion 201–202
scope of exclusion 184–185

Disclaimers 168–182
cosmetic method with therapeutic effect 170–171
EBA, and 180–181
excluded method of medical treatment 174–175
flow measurement 171–172
form of admissible claim 175–178
higher level of abstraction 177–178
implications of using 178–180
importance of 169–170
issue 169–170
legal analysis 182
limiting scope of claims, and 172
methods of medical treatment, and 170–175
‘non therapeutic’, meaning 173–174
omission of step 181–182
surgical methods, and 168–182
use of 175–176
when allowed 175–176
wording of claims, and 171
Dosage regimes
Patents Act 1977 see Patents Act 1977

Enlarged Board of Appeal (EBA)
animals, and 111–112
disclaimers, and 180–181
MEDI-PHYSICS/Treatment by surgery, and 140–148
surgical methods, and 123–124, 136–138, 153
therapeutic methods, and 85–87
EU Biotech Directive 221–223
aim of 221
methods of medical treatments 221–222
morality, and 222–223
ordre public 222–223
European Patent Office (EPO)
jurisprudence 436–442
diagnostic methods 439–440
gene expression testing 224–227
legislative history 436
medical treatment 5–6
second and further medical uses 440–442
surgical methods 438–439
therapeutic methods 436–438
United Kingdom courts, and 442
Excluded surgical step 158–168
applicable national laws 161–162
diagnostic methods 160–161
existence of surgical steps in claim 159–161
insertion of device into human body 162–163
interaction with body 158
MEDI-PHYSICS/Treatment by surgery 165–168
method for conditioning gas 163
non-surgical steps, and 159–160
ratio legis 161–162
surgical steps defined as excluded surgical treatments 162–164
surgical steps not defined as excluded surgical treatments 164–165
Genetic diagnostic testing 223–227
challenges 228
EPO jurisprudence 224–227
morality, and 223–227
nucleic acid 224–226
ordre public, and 223–227
socio-economic consequences of patenting 226–227
Hippocratic Oath 61–62
methods of medical treatment 63–65
specific to medical profession 63–64
Judicial determination of exclusion 433–436
Australia 434
New Zealand 434
United Kingdom 433–434
PAT 434
United States of America 435–436
Manner of new manufacture 287–331
Australia 321–330
ethical considerations 324
law 299
public policy 323
vendible test 322–323
biological subject matter 301–304
biotechnological subject matter 301–304
commercial object requirement 297–298
Commonwealth 321–330
contraceptive methods 315–321
arrangement of pills on card 317–319
hormonal drugs 316
method of medical treatment, whether 316
pack claims 316, 317–320

Eddy D. Ventose - 9780857938015
Downloaded from Elgar Online at 09/01/2019 10:21:41AM
via free access
Index

process claims 316
royal prerogative 317
setting limits 320–321
diagnostic methods, and 291–292
defaith, and 290–291
demise of commercial object
requirement 299–301
economic rationale of patent system 300–301
ethical grounds 308–315
extraction of lead 297
medicine, meaning 288
micro-organisms 302–303
morality: emerging concept 309–311
morality: legal justification 311–314
morality: necessary or hindrance, whether 314–315
morality, relevance 308
nature of exclusion 288–295
New Zealand 321–330
EISAI 327–329
new use claim 325–326
novelty 326
public policy 324–325
second medical indication 327–329
second medical use patents 325–329
Swiss-type claims 327,329
Patent Office Practice 287, 304–307
Act of 1977 307
contraception 305
Examiners, role of 307
improved wool yield 304–305
PAT, role of 307
procedure 306–307
reduction of gastric secretion 306
public policy grounds 308–315
rationale for exclusion 295–315
sound treatment 302–303
Statute of Monopolies 296
statutory interpretation 296–304
statutory regime 296
test for general patentability 300
treatment in animals 293–295
treatment in humans 289–292
vendible product 298
widening conception of manufacture 298
Medical treatment
EPO jurisprudence 5–6
future of medical patents 7–8
patent protection 1–2
arguments 2–5
direct control 5
public health, and 3–4
patentability 6–7
Medicine
meaning 288
New Zealand
economic rationale 446
judicial determination of exclusion 434
manner of new manufacture see Manner of new manufacture
Patent Appeal Tribunal
judicial determination of exclusion 434
Patent Office Practice, and 307
Patents Act 2004 332–337
basis of origin of exclusion, and 333–334
comparison with pre-1977 law 333–338
interpretation 332–333
revision of EPC, and 332
Patents Act 1977 334–338
Actavis v Merck see Actavis v Merck
animals, treatment of see also Animals 336
application of exclusion 338–344
defining therapy 339–340
ex post facto rationalisation 338–339
inherent contradictions 339
method of treatment by therapy 339–342
pharmaceutical inventions 338
taxol 340–342
Bristol-Myers Squibb, and 361–370
cosmetic methods 337–338
Diagnostic methods 336–337, 343–344
dosage regimes 356–372
Actavis v Merck 361–372
issues for courts 357
second medical treatment 357–360
further reformation of exclusion 335–336
humans, treatment of 336
industrial application 335
invention 334–335
methods of treatment by surgery 342–343
new law of patents 334
reformulation of exclusion 335
second and further medical uses 345–356
applying requirements of Swiss-type claim 353–355
codification of EISAI/Second medical indication 355–356
current UK approach 348–353
desire to achieve conformity 347–348
doctrinal issues 346–356
dosage regime 352–353
EISAI 345–346
manufacture of medicament 353–354
new therapeutic application 354–355
novelty in end result 350–351
only first medical use protected 346
pharmaceutical inventions 347
principle, matter of 347
reaffirmation by Court of Appeal 349–353
reluctant application by Jacob J 348–349
second medical indication 345–346
Swiss-type claim 351–352
taxol 349–353
Public health considerations 433
Royal prerogative contraceptive methods and 317
Second and further uses see also
Second and further medical uses claims allowable, whether 252–253
‘compounds’ 232
deVICES 246–254
dosage regimes 255–285
contovery over 255–256
decoisions of TBAs 279–280
defining 280–281
differences between EPC 1973 and EPC 2000 281–282
end of Swiss type claims 282–283
EPC 1973 261–269
EPC 2000 259–261, 269
first medical uses 273–274
new technical effect 281
relationship with medical treatment exclusion 271–273
second and further medical uses 256–259
specific uses under EPC 2000 274–277
Swiss-type claims 277–279
EISAI 235–237
EPO jurisprudence, and 440–442
extending reach of EISAI principle 244–246
administration of vaccine to sero-positive pigs 244–245
initial exclusion 234–235
instruments 246–254
claims allowable, whether 252–253
recent changes 253
 legislative history 230–234
new medical technology 285–286
not applicable to products which are not medicaments 251
not falling within ratio legis of ESAI/second medical indication 249–251 origin 234–237
narrow interpretation 126–127
non-insignificant 129–130
pericardial access 124
physician, role of 153–155
polarized 129Xe 123–124
purpose of intervention 132–136
ratio legis 132–134
relevance 134–136
reason for exclusion 117
significance 157
surgery, meaning 128–129
therapeutic treatment, and 130–131
travaux preparatoires 120
treatment, meaning 125–126
Swiss-type claims 237–244
acceptable form 242–244
adsorbent, use of 238–239
anti-tumoural agent 242–243
L (-) carnitine 241
manufacture of medicament 238–239
new therapeutic application 239–242
requirements 237–244
sea lice infestation 242
serotonin receptor 240–241
Therapeutic methods 71–116
animals see Animals
contraceptive methods see Contraceptive methods
cosmetic methods see also Cosmetic methods
defining 75–78
EPO jurisprudence 436–438
implantable devices 78–88
application 86
blood assistance method 84–85
EBA 85–87
need for functional link or nexus 79–80
not patentable 80–81
pacemaker 81–84
patentable 81–85
rapid acquisition resonance imaging 87
therapeutic effect 88
involvement of medical practitioners 88–89
legislative history 73–75
maintenance of health 77–78
medical treatments 73
methods of therapy 73–74
new medical technology see New medical technology
‘physical methods’ 74
restoration of health 77–78
scope of exclusion 75–77
therapy, meaning 74–75
treatment by therapy, meaning 72–73
Therapy meaning 74–75, 75–76
Treatment by therapy meaning 72–73
TRIPs Agreement 47, 54
United Kingdom courts
EPO jurisprudence, and 442
United Kingdom Patents Act 2004 see Patents Act 2004
United States of America 374–432
applying Bilski v Kappos 422–430
applying machine-or-transformation test 425–428
diagnosis for curative purposes 420
interpreting claims 423–424
mental step 429–430
natural phenomena 428–429
relevance of machine-or-transformation test 422–423
balancing of competing values and interests 445
constitutional guarantee 392–393
constitutional power 392–431
creation of fever in human body 379
diagnostic methods after Bilski v Kappos 412–430
analysis of gene sequences 421–422
defining diagnostic methods 413–415
mathematical formula 417–418, 419
laws of nature 416–417
machine-or-transformation
  test 415–416
natural phenomena 416–422
process for curing synthetic
rubber 418–420
diagnostic methods in Federal
  Circuit after Laboratory
  Corporation v Metabolite
  Labs 400–409
diagnostic methods in Federal
  Circuit before Laboratory
  Corporation v Metabolite
  Labs 394–395
diagnostic methods in Supreme
  Court 396–400
‘application of a law of nature’
  399
‘correlate’, meaning 396–399
‘natural phenomenon’ 399–400
‘process’ 399
public interest considerations
  400
658 patent 396
Dick 378
ex parte Brinkerhoff 378–380
ex parte Scherer 374, 375
Federal Circuit 394–395
algorithm 394, 408
diagnostic claims 394–395
diagnostic methods after
  Laboratory Corporation v
  Metabolite Labs 400–409
fundamental principle 407
machine-or-transformation test
  404
mental process 403–404
phenomena of nature 401–403,
  406
transformation 407–408
‘warning’ steps 408–409
Genomic Research and Diagnostic
  Accessibility Act 390–392
contrary to spirit of MPAA 392
immunity from infringement
  391
reason for 390
research on genetic sequences
  391
retrospective application
  391–392
infringement 390
inhaled ethers 375–376
initial exclusion 375–378
initial judicial determination
  375–382
involvement of human body
  380–381
judicial determination of
  exclusion 434
legal requirements of
  patentability 431
legislative history 383–384
legislative intervention
  382–392
MPAA 382
MPAA 432
medical or surgical method
  380
nature of exclusion in
  section 387(c) 384–390
cadavers 387
defendant 386
hybrid claims 389–390
legislative intention 385–390
medical activity 384–385,
  386–387
patented use of composition of
  matter 387–389
three-pronged approach
  385
patent protection reasserted
  380–382
POBA 374
professional ethics 431
public policy 431
section 1, Patent Act 392–393
Senate Bill 1334 383
Supreme Court
categories of inventions eligible
  for protection 410
diagnostic methods after Bilski v
  Kappos 412–430
machine-or-transformation
  test 410–411
process, test for 411
standard for patentability in
  Bilski v Kappos 409–412
surgical instruments 377
USPTO 374